Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 Mar 26;6(5):10.1158/1940-6207.CAPR-12-0322. doi: 10.1158/1940-6207.CAPR-12-0322

TABLE 1.

Serum Levels of Erlotinib and Its Major Metabolite OSI-420 in Female Sprague-Dawley Rats

(a) Erlotinib, 6 mg/kg BW/day
Hours After Final Gavage Erlotinib OSI-420
2 708 ± 48* 133 ± 17
4 427 ± 19 88 ± 13
8 277 ± 102 58 ± 19
24 25 ± 9 18 ± 5
48 0 10 ± 4
(b) Erlotinib, 42 mg/kg BW, 1x/week
Hours After Final Gavage Erlotinib OSI-420
2 1352 ± 96 246 ± 21
4 1060 ± 184 226 ± 32
8 1590 ± 259 323 ± 42
24 470 ± 121 130 ±36
48 52 ± 11 13 ± 4
(c) Controls
None detected
*

Values are ng/ml of serum; mean ± SEM